¹Ì±¹ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
U.S. Aerosol Drug Delivery Devices Market Size, Share & Trends Analysis Report By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1771646
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,950 £Ü 5,509,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,950 £Ü 6,904,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,694,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÃÀå ±Ô¸ð ¹× µ¿Çâ :

¹Ì±¹ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 112¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2030³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 15.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ¹è°æ¿¡´Â È£Èí±â ÁúȯÀÇ À¯º´·ü »ó½Â, ÈíÀԱ⠱â¼úÀÇ Áøº¸, ÇコÄɾî ÀÇ½Ä °íÁ¶, ÀçÅà ġ·á ¼ö¿ä Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¹Ì±¹ÆóÇùȸ Ã߻꿡 µû¸£¸é 2022³â¿¡´Â ¼ºÀÎÀÇ 4.6%ÀÎ ¾à 1,170¸¸ ¸íÀÌ ¸¸¼º ±â°üÁö¿°À̳ª Æó±âÁ¾À» Æ÷ÇÔÇÑ COPD·Î Áø´ÜµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ WHO´Â 2030³â±îÁö COPD, Æó¾Ï, °áÇÙ µîÀÇ »ý¸íÀ» À§ÇùÇϴ ȣÈí±â ÁúȯÀÌ ¼¼°èÀÇ »çÀÎÀÇ °ÅÀÇ 5¸í¿¡ 1¸íÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ÈíÀÔ±â¿Í ³×ºæ¶óÀÌÀú¸¦ Æ÷ÇÔÇÑ ¿¡¾î·ÎÁ¹ ÀåÄ¡ÀÇ º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀçÅà ÇコÄɾ Áß½ÃµÇ°Ô µÈ °Íµµ, ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±âÀÇ Ã¤¿ë È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ȯÀÚ¿Í ÇコÄɾî Á¦°ø¾÷ü´Â ÄèÀûÇÑ °¡Á¤¿¡¼­ÀÇ Ä¡·á¸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, Åë¿øÀÇ Çʿ伺°ú °ü·Ã ÀÇ·áºñ¸¦ »è°¨Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÇÁÆ®´Â È£Èí±â ÁúȯÀÇ Àڱ⠰ü¸®¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ÈÞ´ë °¡´ÉÇÏ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ÀüÀÚ»ó°Å·¡ Ç÷§ÆûÀ̳ª ¿Â¶óÀÎ ¾à±¹ÀÌ ÀÌ¿ë °¡´ÉÇØÁö¸é¼­ ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ´õ¿í ³ô¾ÆÁ³½À´Ï´Ù.

¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±âÀÇ ±â¼úÀû Áøº¸´Â ½ÃÀå ¼ºÀåÀ» ÇöÀúÇÏ°Ô ÃËÁøÇÕ´Ï´Ù. ¾àÁ¦ÀÇ »ç¿ë »óȲÀ» °¨½ÃÇÏ°í º¹¾à ¾ÖµåÈ÷¾î·±½º¸¦ Çâ»ó½ÃŰ´Â ¼¾¼­¸¦ °®Ãá ½º¸¶Æ® ÈíÀԱⰡ Á¡Á¡ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å¿¡´Â µà¾ó è¹ö DPI, È£Èí ÀÛµ¿½Ä MDI, ģȯ°æ ÃßÁøÁ¦ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¾à¹° Àü´ÞÀÇ È¿À² ¹× ȯÀÚÀÇ Æí¸®¼ºÀ» ³ôÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ÇöÀç ¹Ì±¹ º´¿ø¿¡¼­ ³Î¸® äÅõǰí ÀÖ´Â ¿¡¾î·ÎÁ¨ÀÇ Áøµ¿ ¸Þ½Ã½Ä ³×ºê¶óÀÌÀú ±â¼úÀº ÀΰøÈ£Èí ȯÀÚ³ª ºñÀü±â ȯÀÚÀÇ Ä¡·á¸¦ °³¼±ÇÏ´Â ±â¼ú Çõ½ÅÀÇ ÇÑ ¿¹ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ÀåÄ¡¸¦ º¸´Ù °£´ÜÇÏ°í ½Ç¿ëÀûÀÎ °ÍÀ¸·Î ¸¸µé¾î ȯÀÚ³ª ÇコÄɾî Á¦°øÀÚÀÇ Ã¤¿ëÀ» ÃËÁøÇÕ´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ¹Ì±¹ ½ÃÀå¿¡ È£¿µÇâÀ» ÁÖ¾ú½À´Ï´Ù. COVID-19¿Í °ü·ÃµÈ È£Èí±â ÁúȯÀÌ Áõ°¡Çϰí, ƯÈ÷ Áö¼ÓÀûÀΠȣÈí Äɾ ÇÊ¿ä·Î Çϴ õ½ÄÀ̳ª COPDÀÇ È¯ÀÚ¿¡ ¿µÇâÀ» ÁÖ¾ú±â ¶§¹®¿¡ ÈíÀÔ±â¿Í ³×ºæ¶óÀÌÀú ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. ÀçÅà ÇコÄÉ¾î ¹× ¿ø°Ý ÀÇ·á·ÎÀÇ ½ÃÇÁÆ®´Â, ÈÞ´ëÇü ¹× ½º¸¶Æ® ÈíÀÔ µð¹ÙÀ̽ºÀÇ Ã¤¿ëÀ» ÃßÁøÇß½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀº °ø±Þ¸ÁÀ» È¥¶õ½ÃŰ°í ¿øÀÚÀç ºÎÁ·°ú »ý»ê Áö¿¬À¸·Î À̾îÁ® ½ÃÀå ¼ºÀåÀ» ÀϽÃÀûÀ¸·Î Á¦¾àÇß½À´Ï´Ù. °Ô´Ù°¡ º´¿øÀº Áß¿äÇÑ Ä¡·á¸¦ ¿ì¼±½ÃÇ߱⠶§¹®¿¡ ±ä±Þ¼ºÀÌ ¾ø´Â È£Èí±â Ä¡·á ¹× óġ°¡ °¨¼ÒÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ÁÂÀý¿¡µµ ºÒ±¸Çϰí ÀÌ À§±â´Â µðÁöÅÐ ÇコÀÇ ±â¼ú Çõ½ÅÀ» °¡¼ÓÈ­ÇÏ°í ¹Ì±¹ ½ÃÀåÀÇ Àå±âÀû Àü¸ÁÀ» µÞ¹ÞħÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ¹Ì±¹ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ¹Ì±¹ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Market Size & Trends:

The U.S. aerosol drug delivery devices market size was estimated at USD 11.27 billion in 2024 and is expected to grow at a CAGR of 15.1% from 2025 to 2030. This is attributed to the rising prevalence of respiratory diseases, advancements in inhaler technology, increasing healthcare awareness, and the growing demand for home-based treatments. According to estimates from the American Lung Association, in 2022, approximately 11.7 million people, or 4.6% of adults, were diagnosed with COPD, including chronic bronchitis and emphysema.

In addition, the WHO projects that by 2030, life-threatening respiratory diseases such as COPD, lung cancer, and tuberculosis will be responsible for nearly one in five deaths worldwide. Such factors contribute to the widespread adoption of aerosol devices, including inhalers and nebulizers. The growing emphasis on home healthcare contributes to the increased adoption of aerosol drug delivery devices.

Patients and healthcare providers are seeking treatments administered in the comfort of home, reducing the need for hospital visits and associated healthcare costs. This shift drives demand for portable, user-friendly aerosol delivery devices that facilitate self-management of respiratory conditions. The availability of e-commerce platforms and online pharmacies has further enhanced accessibility to these devices.

Technological advancements in aerosol drug delivery devices significantly propel market growth. Smart inhalers with sensors to monitor medication usage and improve adherence are becoming increasingly prevalent. Innovations include dual-chamber DPIs, breath-actuated MDIs, and environmentally friendly propellants. These technologies enhance drug delivery efficiency and patient convenience. For instance, Aerogen's vibrating mesh nebulizer technology, now widely adopted in U.S. hospitals, exemplifies innovation in improving treatment for ventilated and non-ventilated patients. Such advancements make devices more straightforward and practical, encouraging patient and healthcare provider adoption.

The COVID-19 pandemic had a positive impact on the U.S. market. The demand for inhalers and nebulizers surged as COVID-19 and related respiratory conditions increased, particularly affecting patients with asthma and COPD who required ongoing respiratory care. The shift toward at-home healthcare and telemedicine drove the adoption of portable and smart inhalation devices. However, the pandemic disrupted supply chains, leading to raw material shortages and production delays, temporarily constraining market growth. In addition, hospitals prioritized critical COVID-19 care, causing a decline in non-urgent respiratory treatments and procedures. Despite these setbacks, the crisis accelerated digital health innovation and supported the long-term outlook of the U.S. market.

U.S. Aerosol Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aerosol drug delivery devices market report based on type, application, and distribution channel:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. U.S. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

Chapter 5. U.S. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

Chapter 6. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â